Industry9 min read
Lilly Sues 6 Retatrutide Sellers: Who's Affected
Eli Lilly filed six suits on August 12 over retatrutide sales. The named defendants, the payment-processor ask, and what actually changes for buyers.
Peptide Industry News
Brand launches, primer pieces, broader coverage.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Industry News
Industry9 min read
GLP-1 Antitrust Suit Tossed: What Changes for Buyers
A Texas judge dismissed Strive's antitrust case against Lilly and Novo, ruling compounded GLP-1s never competed with the branded drugs at all.
Industry5 min read
Peptide Vendor Code Names Decoded: GLP-3, MHC-3 RT & More
GLP-3 RT, ION-3R, EZP-3P and R-30 are the same compound. A decoder for every obfuscated vendor SKU, and what each one actually costs per mg.
Industry5 min read
How to Verify a Peptide COA: 6 Checks
A vendor founder went to prison for forging lab certificates. Six checks that separate a real Certificate of Analysis from a PDF that proves nothing.
Industry8 min read
Compounded GLP-1 State Laws: Who Restricts What
California codified a stricter copy rule, Ohio suspended 30+ licenses, Washington issued stop-service orders. The state layer now gates compounded GLP-1s.
Industry7 min read
CagriSema vs Tirzepatide: REIMAGINE 4 Diabetes Data
Novo's amylin/GLP-1 combo matched tirzepatide on weight but missed on blood sugar in the 68-week REIMAGINE 4 head-to-head. What it means for buyers.
Industry7 min read
Pfizer Kills Oral GLP-1 Peptide: What's Left in Pipeline
Pfizer axed its ex-Metsera oral GLP-1 peptide and a phase 2 GIPR antagonist. What survived the cut, and what it changes for research-peptide sourcing.
Industry7 min read
What Doctors Think About Peptides: New Survey Data
48% of physicians say patients disclosed peptide use last year — and 84% got their information from influencers, not doctors. The full survey data.
Industry7 min read
Novo Sues Lilly Over GLP-1 Ads: The Dose Mismatch
Novo asked a court to halt Lilly's GLP-1 ads for pitting max-dose tirzepatide against outdated semaglutide doses. What the trial data actually shows.
Industry8 min read
Are Peptides Legal in the US? What the FDA Vote Means
Most peptides aren't FDA-approved drugs — which isn't the same as illegal. The plain-English answer, and what the FDA's July vote did and didn't change.
Industry4 min read
Buy Peptides With Crypto: Vendors & Discounts
Card networks keep dropping peptide sellers, so crypto is now the default. Which vendors take Bitcoin, who adds a crypto discount, and how it works.
Industry6 min read
FDA Panel Backs 6 Peptides for Compounding, Rejects DSIP
FDA advisers backed 6 of 7 peptides for compounding — Semax and Epitalon included — and rejected DSIP, all over staff objections. Every vote tally.
Industry5 min read
Peptides for Long COVID: What the Trials Show
BPC-157, MOTS-c and microdosed GLP-1s are marketed for Long COVID while semaglutide and tirzepatide trials run. What's studied, what isn't.
Industry5 min read
GLP-1 Use Hits Record 11% as US Obesity Rate Falls
GLP-1 use hit a record 11% of US adults as obesity fell to 36.4% — Gallup's first decline. What the surge means for access, cost, and cheaper routes.
Industry5 min read
Orforglipron Beats Oral Semaglutide: ACHIEVE-3 Data
The first head-to-head of two GLP-1 pills is out: orforglipron beat oral semaglutide on blood sugar and weight — but at a steeper GI cost.
Industry7 min read
Medicare GLP-1 Bridge Live: Who Gets the $50 Copay
Medicare's GLP-1 Bridge went live July 1 with a $50 copay — but only ~3.8M qualify, retatrutide isn't covered, and the copay has a catch.
Industry7 min read
Bofanglutide: Biweekly GLP-1 Beats Semaglutide
A 272-patient phase 2b trial found biweekly bofanglutide cut HbA1c more than semaglutide. Here's what the every-2-week GLP-1 means for buyers.
Industry6 min read
Viking's VK3019: New Amylin Drug Enters Trials
Viking started Phase 1 of VK3019, an amylin-calcitonin drug for weight loss. What DACRA means and the amylin peptides you can buy now.